118 related articles for article (PubMed ID: 36533319)
21. Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells.
Fagundes TR; Madeira TB; Melo GP; Bordini HP; Marinello PC; Nixdorf SL; Cecchini AL; Luiz RC
Bioorg Chem; 2022 Mar; 120():105576. PubMed ID: 34979447
[TBL] [Abstract][Full Text] [Related]
22. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
23. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment.
Olszewska-Słonina DM; Styczyńisk J; Drewa TA; Olszewski KJ; Czajkowski R
Acta Pol Pharm; 2005; 62(6):473-83. PubMed ID: 16583988
[TBL] [Abstract][Full Text] [Related]
24. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.
Chartrain M; Riond J; Stennevin A; Vandenberghe I; Gomes B; Lamant L; Meyer N; Gairin JE; Guilbaud N; Annereau JP
PLoS One; 2012; 7(5):e36762. PubMed ID: 22675422
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the expression and intracellular localization of a 44-kDa calmodulin binding protein during exponential growth and quiescence (G0).
Laquerre S; Lagacé L; Chafouleas JG
Biochem Cell Biol; 1995; 73(1-2):91-104. PubMed ID: 7662320
[TBL] [Abstract][Full Text] [Related]
26. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
27. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
[TBL] [Abstract][Full Text] [Related]
28. Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes.
Respondek M; Beberok A; Rzepka Z; Rok J; Wrześniok D
Pathol Oncol Res; 2020 Jul; 26(3):1465-1474. PubMed ID: 31432325
[TBL] [Abstract][Full Text] [Related]
29. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.
Chi M; Ye Y; Zhang XD; Chen J
Drug Des Devel Ther; 2014; 8():255-62. PubMed ID: 24600206
[TBL] [Abstract][Full Text] [Related]
30. The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.
Wouters J; Stas M; Gremeaux L; Govaere O; Van den Broeck A; Maes H; Agostinis P; Roskams T; van den Oord JJ; Vankelecom H
PLoS One; 2013; 8(10):e76550. PubMed ID: 24098529
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Ryabaya O; Prokofieva A; Khochenkov D; Abramov I; Zasedatelev A; Stepanova E
Oncol Rep; 2018 Jul; 40(1):385-394. PubMed ID: 29749510
[TBL] [Abstract][Full Text] [Related]
32. Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
Risberg K; Fodstad O; Andersson Y
J Immunother; 2010 Apr; 33(3):272-8. PubMed ID: 20445347
[TBL] [Abstract][Full Text] [Related]
33. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
[TBL] [Abstract][Full Text] [Related]
34. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.
Salvador D; Bastos V; Oliveira H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408947
[TBL] [Abstract][Full Text] [Related]
35. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract][Full Text] [Related]
36. A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.
Saunders MP; Salisbury AJ; O'Byrne KJ; Souliotis VL; Varcoe SM; Talbot DC; Kyrtopoulos SA; Harris AL
Anticancer Res; 1997; 17(6D):4677-80. PubMed ID: 9494588
[TBL] [Abstract][Full Text] [Related]
37. PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo.
Jin JL; Gong J; Yin TJ; Lu YJ; Xia JJ; Xie YY; Di Y; He L; Guo JL; Sun J; Noteborn MH; Qu S
Eur J Pharmacol; 2011 Mar; 654(1):17-25. PubMed ID: 21184754
[TBL] [Abstract][Full Text] [Related]
38. Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.
Cun B; Song X; Jia R; Zhao X; Wang H; Ge S; Fan X
Cancer Biol Ther; 2012 Jan; 13(2):77-84. PubMed ID: 22336909
[TBL] [Abstract][Full Text] [Related]
39. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines.
Campagna R; Salvolini E; Pompei V; Pozzi V; Salvucci A; Molinelli E; Brisigotti V; Sartini D; Campanati A; Offidani A; Emanuelli M
Pigment Cell Melanoma Res; 2021 Nov; 34(6):1039-1048. PubMed ID: 34018676
[TBL] [Abstract][Full Text] [Related]
40. Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.
Skoko J; Rožanc J; Charles EM; Alexopoulos LG; Rehm M
BMC Cell Biol; 2018 Dec; 19(1):28. PubMed ID: 30587121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
